By Daniel Sheehan, Reporter Staff
March 4, 2021
Daniel Sheehan, Reporter Staff
A coalition of eight existing non-profit organizations based in Fields Corner plan to streamline and better coordinate their services, thanks a funding boost from Boston Children’s Hospital. The new group Fields Corner Crossroads hopes to roll out its network after concluding a year-long planning process and transitioning into a three year implementation phase.
Michelle Nadow, president and CEO of DotHouse, Lisette Le, Executive Director of VietAID, and Candice Gartley, Executive Director of All Dorchester Sports and Leadership (ADSL), discussed their vision for the collaborative with the Reporter this week.
BioNJ Announces Diversity, Equity & Inclusion Conference Program
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
BioNJ Announces Diversity, Equity & Inclusion Conference Program
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
FDA approves pembrolizumab as first-line treatment for colorectal cancer
The FDA recently approved the immunotherapy drug pembrolizumab as a first-line treatment for patients with certain types of advanced colorectal cancer. This is the 9th FDA approval supported by Stand Up To Cancer® (SU2C) research.
Patients newly diagnosed with advanced or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer previously would have been prescribed pembrolizumab only after exhausting standard chemotherapy treatments.
The FDA approved pembrolizumab, also known under the brand name Keytruda, as first-line treatment for metastatic MSI-H dMMR colorectal cancer based on early results from a phase III clinical trial, which was partially funded by an SU2C grant.